SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (51990)11/17/2022 4:12:13 PM
From: A.J. Mullen  Respond to of 52153
 
Editas shelves work on a rare eye disease after Phase 1/2 results. Only 3 of 14 patients showed meaningful improvements. Two of the three were homozygous for the relevant mutation. Of the approximately 1500 patients, only 300 are homozygous. Editas figures that's too few for them to pursue independently. They're pausing enrollment in the trial while they look for a partner.

fiercebiotech.com Editas is down 10%, CRSP down 2%


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News